Wockhardt shares rise 10% after Zaynich aids successful liver transplant trial
Wockhardt's shares surged 8.6% after its antibiotic Zaynich successfully treated a US cancer patient, enabling a liver transplant and chemotherapy. The drug is nearing Phase III trials for global approval.
Site référencé: The Economic Times
The Economic Times
Reliance, HPCL, 17 other stocks to go ex-dividend on Thursday. Last chance to qualify for eligibility
13/08/2025
Dollar slips as investors eye September Fed cut
13/08/2025
Essential guide for first-time investors : Understanding mutual funds and their risks
13/08/2025
Spandana Sphoorty Financial raises Rs 400 Crore through rights issue amid oversubscription
13/08/2025
How did India's wealthiest investors perform in June quarter ?
13/08/2025
Banks boost equity investments by 49% in FY25 amid retail FOMO
13/08/2025
